CRS: BJMC
Position: Lab Manager
Position: TB Laboratory Coordinator
CRS:
Position:
1077FF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...
ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...
IMPAACT P1026s, the predecessor of this study, was first approved in 2003. P1026s enrolled over 1000 pregnant/postpartum women,...
Using existing data from A5274 and data obtained from retrospectively testing available biospecimens, we propose the following...
This study will enroll HIV-infected people who do not have evidence of active TB but who are at high risk of developing active...
